Overview

Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastati

Status:
Recruiting

Trial end date:
2024-05-30

Target enrollment:

Participant gender:

Summary

This study is being done to learn more about a new drug called Bapotulimab given in combination with Pembrolizumab. The purpose of this study is to learn if this new combination of drugs is safe for the participants, how it affects the body and to try to find the best dose of the new drug to give to participants and to obtain a preliminary assessment of the tumor response efficacy in the recurrent or metastatic Head and Neck Cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Bayer

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Antibodies
Antibodies, Blocking
Pembrolizumab